The stock of AstraZeneca plc (LON:AZN) is a huge mover today! The stock decreased 0.72% or GBX 30.33 on November 23, hitting GBX 4175.17. About 4.11M shares traded hands or 44.21% up from the average. AstraZeneca plc (LON:AZN) has risen 2.98% since April 25, 2016 and is uptrending. It has underperformed by 2.35% the S&P500.
The move comes after 7 months negative chart setup for the GBX 53.11B company. It was reported on Nov, 23 by Barchart.com. We have GBX 3924.66 PT which if reached, will make LON:AZN worth GBX 3.19 billion less.
AstraZeneca plc (LON:AZN) Ratings Coverage
Out of 30 analysts covering AstraZeneca PLC (LON:AZN), 13 rate it a “Buy”, 4 “Sell”, while 13 “Hold”. This means 43% are positive. GBX 7000 is the highest target while GBX 3700 is the lowest. The GBX 4922.09 average target is 17.89% above today’s (GBX 4175.17) stock price. AstraZeneca PLC has been the topic of 340 analyst reports since July 23, 2015 according to StockzIntelligence Inc. The stock of AstraZeneca plc (LON:AZN) has “Hold” rating given on Thursday, March 24 by HSBC. The firm has “Buy” rating given on Monday, August 10 by Citigroup. The firm has “Buy” rating given on Wednesday, September 14 by Societe Generale. The rating was maintained by Deutsche Bank with “Buy” on Thursday, June 30. The firm has “Underwt/In-Line” rating by Morgan Stanley given on Thursday, September 17. J.P. Morgan maintained it with “Neutral” rating and GBX 3900 target price in Friday, February 19 report. On Wednesday, October 26 the stock rating was maintained by Bryan Garnier & Cie with “Buy”. BNP Paribas maintained the stock with “Outperform” rating in Monday, October 5 report. Oddo & Cie maintained the stock with “Neutral” rating in Friday, September 18 report. AlphaValue maintained AstraZeneca plc (LON:AZN) rating on Thursday, December 31. AlphaValue has “Add” rating and GBX 4817 price target.
Another recent and important AstraZeneca plc (LON:AZN) news was published by Streetinsider.com which published an article titled: “Form 6-K ASTRAZENECA PLC For: Nov 22” on November 22, 2016.
AstraZeneca PLC is a biopharmaceutical company. The company has a market cap of 53.11 billion GBP. The Firm focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas. It has a 26.62 P/E ratio. The Firm has its activities in over 100 countries.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.